Truxima

Truxima (rituximab) is an intravenous infusion used to treat certain autoimmune conditions and cancers by targeting CD20-positive B-cells. As a biosimilar to rituximab, it offers a cost-effective option for patients requiring this therapy. Always consult a healthcare provider for personalized guidance.

Truxima (rituximab) is primarily used to treat autoimmune disorders like rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. It is also prescribed for certain cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. Patients often ask, 'what is rituximab used for' due to its broad therapeutic applications in immune system modulation and oncology.

Truxima works by binding to CD20 proteins on B-cells, reducing inflammation and abnormal cell growth. Many patients notice improved symptoms over time, though individual responses vary. Infusion reactions, such as fever or chills, may occur during or after administration.

Truxima should only be administered under medical supervision due to the risk of serious infusion reactions. Patients with active infections or weakened immune systems may need to delay treatment. Regular monitoring is essential to assess response and manage potential side effects.

Concurrent use of live vaccines or immunosuppressive drugs may reduce Truxima’s effectiveness or increase infection risk. Alcohol and certain medications, like CYP inhibitors, can affect how the body processes rituximab. Always disclose all medications to your healthcare provider before starting Truxima.